Inflammation and Lung Cancer: The Link to Angiogenesis

Dec 10, 2016 by in ONCOLOGY Comments Off on Inflammation and Lung Cancer: The Link to Angiogenesis

Potential linkers Source Functions in inflammation Functions in angiogenesis References TNF-α Macrophages Tumor cells Augments E-selectin and VCAM-1 on ECs to promote leukocyte adhesion and inflammation Induces COX-2 Induces IL-8…

read more

Inflammation and Lung Cancer: Addressing Inflammation with Immunotherapy

Dec 10, 2016 by in ONCOLOGY Comments Off on Inflammation and Lung Cancer: Addressing Inflammation with Immunotherapy

© Springer Science+Business Media New York 2015Steven M. Dubinett (ed.)Inflammation and Lung Cancer10.1007/978-1-4939-2724-1_7 7. Inflammation and Lung Cancer: Addressing Inflammation with Immunotherapy Sherven Sharma1  , Siwen Hu-Lieskovan2  , Steven M. Dubinett3   and Jay Moon Lee4   (1) Division of Pulmonary and…

read more

Inflammation and Lung Cancer: Molecular Pathology

Dec 10, 2016 by in ONCOLOGY Comments Off on Inflammation and Lung Cancer: Molecular Pathology

Fig. 3.1 Inflammation in lung cancer development. Carcinogens in tobacco smoke induce inflammatory damage directly on normal epithelium. Additionally, exposure to tobacco smoke leads to induction and recruitment of proinflammatory…

read more

Progress in Clinical Use of CC Chemokine Receptor 4 Antibody for Regulatory T Cell Suppression

Dec 10, 2016 by in ONCOLOGY Comments Off on Progress in Clinical Use of CC Chemokine Receptor 4 Antibody for Regulatory T Cell Suppression

Target antigens Antibody medicines Tumor types Mechanisms of tumor killing Hematopoietic cell differentiation antigens CD20 Rituximab Non-Hodgkin’s lymphoma ADCC  Tositumomab Non-Hodgkin’s lymphoma 131I  Ibritumomab 90Y CD22 Inotuzumab Non-Hodgkin’s lymphoma Ozogamicin…

read more

Enhancement of Efficacy of Wilms’ Tumor Gene WT1 Product-derived Peptide Cancer Vaccine by Co-administration with Immunopotentiating Agents: Lessons from Mouse Models

Dec 10, 2016 by in ONCOLOGY Comments Off on Enhancement of Efficacy of Wilms’ Tumor Gene WT1 Product-derived Peptide Cancer Vaccine by Co-administration with Immunopotentiating Agents: Lessons from Mouse Models

Fig. 14.1 Strategy of Wilms’ tumor gene (WT1) product-derived peptide vaccination combined with bacillus Calmette-Guérin cell wall skeleton (BCG-CWS). Intradermally (i.d.) injected BCG-CWS binds to Toll-like receptor (TLR) 2 and 4…

read more
Get Clinical Tree app for offline access